ArticleInternational journal of radiation oncology, biology, physics2013
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
Article in International journal of radiation oncology, biology, physics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00369512 (A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Management of Skin Cancer in the High-Risk Patient.Current treatment options in oncology · 2016Pooled it
- Review
- The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.Current treatment options in oncology · 2025Review
- Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Review.Current oncology (Toronto, Ont.) · 2023Review
- Recent Advances in the Diagnosis and Management of High-Risk Cutaneous Squamous Cell Carcinoma.Cancers · 2022Review
- Review
- Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma.Dermatology practical & conceptual · 2021Review
- Novel therapies for advanced skin carcinomas.Postepy dermatologii i alergologii · 2020Review
- [Cutaneous squamous cell carcinoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Review
- Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients.Current oncology reports · 2019Review
- Uncommon Presentation of Metastatic Squamous Cell Carcinoma of the Skin and Treatment Challenges.The American journal of case reports · 2019Article
- Peri - and Intraocular Mutilating Advanced Squamous Cell Carcinoma: "Monsters Inside Your Body"?Open access Macedonian journal of medical sciences · 2018Article
- Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification.Ear, nose, & throat journal · 2017Article
- Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.World journal of clinical cases · 2014Review
- Therapy of advanced squamous cell carcinoma of the skin.Current treatment options in oncology · 2014Review
- Advances in the management of cutaneous squamous cell carcinoma.F1000prime reports · 2014Review
- Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo assess the toxicity profile of erlotinib therapy combined with postoperative adjuvant radiation therapy in patients with advanced cutaneous squamous cell carcinoma. METHODS AND MATERIALS: This was a single-arm, prospective, phase 1 open-label study of erlotinib with radiation therapy to treat 15 patients with advanced cutaneous head-and-neck squamous cell carcinoma. Toxicity data were summarized, and survival was analyzed with the Kaplan-Meier method.
resultsThe majority of patients were male (87%) and presented with T4 disease (93%). The most common toxicity attributed to erlotinib was a grade 2-3 dermatologic reaction occurring in 100% of the patients, followed by mucositis (87%). Diarrhea occurred in 20% of the patients. The 2-year recurrence rate was 26.7%, and mean time to cancer recurrence was 10.5 months. Two-year overall survival was 65%, and disease-free survival was 60%.
conclusionsErlotinib and radiation therapy had an acceptable toxicity profile in patients with advanced cutaneous squamous cell carcinoma. The disease-free survival in this cohort was comparable to that in historical controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.